BioTrillion is a little startup with bold ambitions to advance Healthcare – via Digital Biomarkers. Every human generates massive (“trillions”) amounts of life (“bio”) data that will unlock novel health insights & applications.
We are developing a mobile health technology platform called BioEngine4D – for digitally detecting dangeous drugs, digitally detecting developing diseases, and data driven drug development – by measuring data from life, analyzing it through computational advancements in machine learning and artificial intelligence, and applying it back for life.
What if...1 billion global human lives could be enabled with access to radically novel health insights – using only their smartphone? The solution is looking at you everyday.
Our journey begins in Neurology. The first set of digital biomarkers we are developing (and have developed) offer more effective and scalable applications in Neurology for:
BioTrillion, Inc. was incorporated in December 2017 with our headquarters in San Francisco, CA. We are reimagining Life Sciences through the fundamental principles of many sciences.
Our mission is to empower individuals with enhanced healthcare abilities. Advances in technology have amplified our individual capabilities in many ways, and healthcare should be no exception.Opportunities
We so often think of Healthcare as an industry, that we tend to forget about Healthcare as a purpose.
BioTrillion aims to optimize quality of life and to increase longevity by reframing our approach to health solutions from the Consumer's perspective across 3 key temporal phases: the “Prevention,” “Detection,” and “Intervention” of diseases.
We spend less than 1% of our time in a Medical setting and hope the medical data generated there will lead to enhanced outcomes. Medical data is abundant, but its format is siloed, unstructured, and intermittent. As a result, a massive amount of Medical data is not being adequately connected to our healthcare. Medical settings offer access to tremendous medical experience and clinically-validated diagnostics; however, their utility will always be fundamentally limited given the typical Consumer only spends < 1% of their total time in an actual Medical setting.
The Life setting provides access to something the Medical setting does not — that other 99% of time. It is during this massive gap in time where the signs of developing diseases may be expressed, but go undetected, yielding both clinical and economic opportunities for much more effective (frequent, objective, quantitative) and scalable (accessible, affordable, convenient) consumer health solutions. We believe health solutions of the future will come from within the Life setting, via LIFEdata (sensor-measured information generated from and around life) and its computationally analytic conversion to digital biomarkers.
Today, life information is exponentially transitioning out of an analog world and into a digital one. An increasing number of sensors in our smart devices are entering our Life setting and have the ability to capture many earlier signs of disease in the form of LIFEdata through multiple modalities. These sensors are often disparate and thus limited in perspective when analyzed alone, yet are synergistic in value when analyzed interconnectedly.
BioTrillion is focused on generating LIFEdata from these sensors along with aggregating labelled Medical data, and training BioEngine4D through machine learning and artificial intelligence to statistically and digitally measure disease development and disease response to drugs.
BioEngine4D is being developed as a more effective and scalable health technology solution — for Consumers. We aim to augment Consumers' own self-healthcare abilities, helping to bridge the gap between the Medical and Life settings. Afterall, no one will care more for your health than you.
Novel technologies that have been synergistically applied to traditional domains have yielded entirely new opportunities to solve old problems in new ways. We see an inflection point in the future where the health value of data generated in the Life setting will exceed that of data generated in the Medical setting. And where innovative solutions to measuring potential diseases will be oriented around frequency, objectivity, quantification (efficacy) and accessibility, affordability, convenience (scalability) - yielding better outcomes for all. Solutions that — in retrospect — will make us realize that our health has been "in the dark" 99% of the time.
We believe that Data from Life should be Data for Life.
More about BioEngine4D